Zelapar, Hycamtin

Zelapar trị Parkinson, dùng chung với ledopa/carbidopa, - Hycamtin với Cistaplin trị ung thư tử cung giai đoạn IV-B, - Fluoroxetine trị bệnh Anorexia nervosa (biếng ăn tâm thần), - FDA bỏ Canasa 500mg nhưng vẫn cho dùng thuốc nhét Canasa 1000mg, Nexavar trong việc điều trị ung thư gan di căn, Nexavar cũng cho dùng điều trị ung thư thận trầm trọng, - Myvax chữa ung thư máu trong việc điều trị miễn dịch ung thư máu Follicular non-Hogkin lymphoma. - Ngoài ra FDA cũng cho phép thử nghiệm Panitumumab trong việc dùng kháng thể tạo sinh từ...
Nội dung trích xuất từ tài liệu:
Zelapar, Hycamtin Zelapar, Hycamtin - Zelapar trị Parkinson, dùng chung với ledopa/carbidopa, - Hycamtin với Cistaplin trị ung thư tử cung giai đoạn IV-B, - Fluoroxetine trị bệnh Anorexia nervosa (biếng ăn tâm thần), - FDA bỏ Canasa 500mg nhưng vẫn cho dùng thuốc nhét Canasa1000mg, Nexavar trong việc điều trị ung thư gan di căn, Nexavar cũng chodùng điều trị ung thư thận trầm trọng, - Myvax chữa ung thư máu trong việc điều trị miễn dịch ung thư máuFollicular non-Hogkin lymphoma. - Ngoài ra FDA cũng cho phép thử nghiệ m Panitumumab trong việcdùng kháng thể tạo sinh từ người, tác dụng yếu tố thụ thể biểu bì tăngtrưởng. New Parkinson Disease Treatment Approved The FDA has approved Valeant Pharmaceuticals’once-daily Zelapar(selegiline HCl) orally disintegrating tablets as adjunct therapy for Parkinsondisease patients being treated with levodopa/carbidopa who demonstratedeterioration in their response to therapy. Zelapar has been shown to reduce “off” time an average of 2.2 hoursper day using Zydis technology, which allows the tablets to dissolve withinseconds in the mouth and deliver more active drug at a lower dose. Expanded Indication Approved for Hycamtin The FDA has approved GlaxoSmithKline’s Hycamtin (topotecanHCl) in combination with cisplatin for the treat ment of stage IV-B,recurrent, or persistent carcinoma of the cervix that is not amenable totreatment with surgery and/or radiation therapy. Fluoxetine Use in Recovering Anorexia Nervosa Patients A study published in the JAMA evaluated fluoxetine in treatingpatients with anorexia nervosa following weight restoration. Therandomized, double-blind, placebo-controlled trial compared 49 patientswith anorexia nervosa who received fluoxetine with 44 patients takingplacebo for up to 1 year as outpatients. Similar percentages of patientsassigned to fluoxetine and placebo maintained a body mass index of at least18.5 and remained in the study for 52 weeks (P = 0.57) with no significantdifference observed between fluoxetine and placebo in time-to-relapse. Canasa 500 mg Suppository Discontinued Axcan Scandipharm has discontinued its Canasa (mesalamine) 500mg suppository. Canasa will still be available as a 1,000 mg suppository,indicated for the treatment of active ulcerative proctitis. Fast Track Status Granted for Nexavar The FDA has granted fast track status to Bayer Pharmaceuticals andOnyx Pharmaceuticals’ Nexavar (sorafenib) tablets for the treatment ofmetastatic hepatocellular carcinoma. Nexavar is approved for the treatmentof advanced renal cell carcinoma. Fast Track Status Granted for MyVax The FDA has granted fast track status to Genitope Corporation’sMyVax, a personalized immunotherapy for the treatment of follicular non-Hodgkin lymphoma (fNHL). Priority Review Granted for Panitumumab The FDA has accepted the BLA and granted priority review forAmgen’s panitumumab, an investigational fully human monoclonalantibody that targets the epidermal growth factor receptor. The BLAwas submitted for the treatment of metastatic colorectal cancer patientswho have failed previous chemotherapy, including oxaliplatin- and/oririnotecan-containing regimens. Ds Trịnh Nguyễn Ðàm Giang